NEW YORK – Inflammatix said Thursday that it has inked a contract worth up to $72 million with the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to further develop and commercialize its sample-to-answer HostDx molecular testing system.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.